U.S. Markets closed

Incyte Corporation (INCY)

NASDAQ Global Select - NASDAQ Global Select Real Time Price. Currency in USD
Add to watchlist
123.86+2.97 (+2.46%)
At close: 4:00PM EDT

123.87 +0.01 (0.01%)
After hours: 5:05PM EDT

People also watch
VRTXBMRNALXNREGNSGEN
  • M
    Michael-P
    Michael-P

    Tax repatriation holiday in the works... will spur bio-tech M&A...

    ... "“repatriation”, would tax corporate earnings that are being stored abroad when that money returns to the U.S. and use the money to modernize the country’s infrastructure. " (The Hill)

    http://thehill.com/policy/transportation/347361-dem-lawmaker-renews-push-for-infrastructure-tax-package

    Imageidolos-frases
  • A
    Anonymous
    Anonymous
    Week ana half to ESMO abstract release. What we're looking for is ECHO 204 "final" report. We already know that the ORR will be 65+% (vs historical in the 40s for Keytruda alone). In the earlier reports, all responses were ongoing. If that continues, well, from my keyboard to G.d's eye. But anything over 50% would be excellent. From the way Merck responded after the results were in, I'd guess that it'll be 60-80% (this can be tricky to gin up a historical comparison for, because there's a superposition of the usual relapse distribution over a substantial "no relapse" number for Keytruda).

    Since I'm a bull, that 60+ or so is the number of ongoing responses that I think would generate enthusiasm for Incyte. Essentially, a repeat of 65+% ORR and 60+% persistence of response as of the interim review of the phase 3 (probably Spring '18) would support "invoking the slaughter rule" and getting epac to market most of a year earlier than generally anticipated.
  • T
    Tom
    Tom
    sell the rips will continue until, retake of 200dma, to many taken to the woodshed on margin
  • T
    Tom
    Tom
    119s again on L2, going back to lod
  • m
    madeoff
    madeoff
    Maddi: Buy out any day now, ooooooooooo ok?
    Maddi -- $140 yet?
  • T
    Tom
    Tom
    hey hey hey, ibb GREEN, dow GREEN, s&P GREEN, NAZ, basically even.....INCY RED yet again....lower highs and lower lows STILL IN PLAY
  • M
    Michael-P
    Michael-P
    Look at that - above the 200 mda ... Look again, rising stock price... INCY Rising all the way into Labor Day weekend, as will the S&P & DOW...Let the runners run... INCY is on sale, lots of buying kicking in.
    Imageidolos-frases
  • T
    Tom
    Tom
    no retake of 200dma ,more new lows coming
  • A
    Anonymous
    Anonymous
    Thing about trading ranges--that's where the stock price is when nothing's happening. No need for an explanation of any move within the range. Now, in the last week we've had let's see...sharpest war scare in a few years, disappointing result of a competitor's IO drug combo trial, disassembly of US executive (with a pot-shot at drug pricing tweeted out), domestic terrorism, foreign terrorism.... And a lot of INCY is in "hot stock"-oriented portfolios, which are weak hands by definition. Seems like plenty of reasons for leaving the channel, all real and all unrelated to the actual business of Incyte.

    And for all that, INCY is still above the post-CRL low.
  • D
    DQSjr
    DQSjr
    Imagerazle-dazle
  • T
    Tom
    Tom
    ESMO will be nothing more pump and dump, just like, ASH, ASOC,AARC
  • T
    Tom
    Tom
    where is 140?????
  • B
    B
    B
    Imagecomfort-ings
  • A
    Anonymous
    Anonymous
    On the subject of range-bound, take a look at INCY's price behavior since the post-CRL bottom. I see lower highs and higher lows, which is pretty much the definition of drifting.

    Of course, I expect the ESMO abstract release to be the next catalyst. If it is disappointing (say, less than 6-month median response duration), there could be a meaningful drop. That's sorta within the realm of possibility, but in that case you'd really have expected Merck to have gone with 2 smaller phase 3s (best approach for eventual approval) rather than one large one (offers possibilities of shortcuts if results are dramatic). If the abstract reveals mildly favorable results, it should basically just shift the range upward by about as much as the apparent disagreement between Incyte and Lilly on what to do about responding to the CRL shifted it down. Spectacular results (>80% of responses continuing at data cutoff) could generate a pop.

    Obvious wild card in the near term is response to the CRL. As before, ANYTHING that decreases uncertainty would be good (although a lawsuit against FDA might turn my face minty green). I see that NCT02265705, the phase 3 for Chinese licensing, is being kept open, now about 10 months after final data collection. There's probably no result from that trial that could turn FDA around, but an outcome announcement would open a path to Chinese sales and quite possibly (since the analysis would mostly have been done post-CRL) give a strong clue to what the parties intend to do moving forward.

    Not much from the deep pipeline figures to move the needle, but in the front-row pipeline I don't think there's been a full presentation of the studies that led to the itacitinib ('110) trial against GvHD (NCT03139604). The preliminary presentation was good, but not spectacular. Still, since the leak about existence of '110 was one of the hammer blows in "The Bad Conference Call," it would be a pleasant irony to see news about the same candidate restore the prior uptrend.
  • M
    Michael-P
    Michael-P

    Gilead: Road To $100 -- From Seekingalpha

    "...Incyte makes a lot of sense and isn’t a ton of ‘risk’ in that it has an impressive portfolio and pipeline, much of which have plenty of overlap with Gilead’s existing products... Incyte is the long and steady play."

    https://seekingalpha.com/article/4100043-gilead-road-100?auth_param=1e7tqa:1cpdohc:1b0bc8d8f7c81398d02afcf133477c0d&uprof=45&dr=1#alt1

    Gilead: Road To $100
    Gilead might have an activist investor.Dan Loeb fits the mold.He’ll push for a buyout and there are two prime candidates.
    seekingalpha.com
  • T
    Tom
    Tom
    selling into every rip, means cleaning out all those on margin
  • D
    DQSjr
    DQSjr
    We must be getting close to a deal...Tommy's negative posts have increased and he really comes out in force on down days. Is he anxious? Worried? Working for the group putting a deal together? Conspiracy? Nobody hangs around since the low teens getting hammered calling for a fall in SP this long. Who's buying INCY Tommy??
  • M
    Maddison
    Maddison
    OT..Please pray for the injured/deceased in Barcelona today... The barbaric terrorists in this world must not win!
  • D
    DQSjr
    DQSjr
    Still in our range and some interesting activity taking place Level II showing buying taking place on the drops.
    Have to believe until GILD makes/announces a purchase...INCY still a top contender and we ride that possibility. We might find someone else comes out and beats GILD to the punch. Until such time...watch the moves associated with "volume" and what is moving the price. Ignore Tommy...he only comes out on Red Days with nothing but agenda driven commentary.
  • H
    Hailey
    Hailey
    Things seem to be getting overextended for INCY. This is so frustrating trying to find trade ideas. I've subscribed to some email newsletters which helps me with new stock ideas. awe-some*sto-cks is the one i like best.